onc Videos

Videos

Erika Hamilton, MD, Sarah Cannon Research Institute

Videos

HER3-DXd for Metastatic Breast Cancer Across Subtypes

06/05/2023

At the 2023 ASCO Annual Meeting, Erika Hamilton, MD, discusses the antibody drug conjugate HER3-DXd, or patritumab deruxtecan.

At the 2023 ASCO Annual Meeting,...

06/05/2023

Oncology

Videos

Teclistamab Plus Talquetamab to Simultaneously Target BCMA and GPRC5D in Patients With R/R Multiple Myeloma

06/04/2023

At the 2023 ASCO Annual Meeting, Yael C Cohen, MD, presents results of the RedirecTT-1 study of the combination of teclistamab and talquetamab for the treatment of patients with R/R multiple myeloma.

At the 2023 ASCO Annual Meeting,...

06/04/2023

Oncology

Videos

PALOMA Study Identifies Recommended Phase 2 Dose of Subcutaneous Amivantamab for Advanced Solid Malignancies

06/04/2023

Anna Minchom, MBBCh, MRCP, MD(Res), discusses updated safety results from the PALOMA trial and the identified recommended phase 2 dose for subcutaneous biweekly administration of amivantamab for patients with advanced solid malignancies.

Anna Minchom, MBBCh, MRCP,...

06/04/2023

Oncology

Joshua Sabari, MD, NYU Langone Health, New York, NY

Videos

Mortality on Osimertinib for Patients With EGFR-Mutant NSCLC

05/30/2023

Joshua Sabari, MD, NYU Langone Health discusses mortality among patients with EGFR-mutated advanced non-small cell lung cancer after starting first-line treatment with osimertinib.

Joshua Sabari, MD, NYU Langone...

05/30/2023

Oncology

Videos

Feasibility of Patient-Reported Outcomes for Acute Graft-Versus-Host-Disease

05/30/2023

Betty K. Hamilton, MD, Cleveland Clinic, Cleveland, Ohio, discusses the findings of a pilot trial analyzing patient-reported outcomes for the management of patients with acute graft-versus-host-disease.

Betty K. Hamilton, MD, Cleveland...

05/30/2023

Oncology

Rebecca Heist, MD, Massachusetts General Hospital, Boston, MA

Videos

Updates in the Treatment of Patients With Small Cell Lung Cancer

05/18/2023

At the 2023 Great Debates and Updates Conference in Chicago, Illinois, Rebecca Heist, MD, discusses developments and advances in the treatment of small cell lung cancer.

At the 2023 Great Debates and...

05/18/2023

Oncology

Edward Garon, MD, University of California, Los Angeles

Videos

Immuno-Oncology Alone for Patients With Lung Cancer and High PD-L1 Expression

05/18/2023

At the Great Debates and Updates in Lung Cancer conference in Chicago, Illinois, Eddie Garon, MD, makes the case for immuno-oncology alone as the optimal course of treatment lung cancer with PD-L1 expression ≥50%.

At the Great Debates and Updates...

05/18/2023

Oncology

Patrick Forde, MD, Johns Hopkins Medical Institute, Baltimore, MD

Videos

Chemotherapy Plus Immuno-Oncology for Lung Cancer With High PD-L1 Expression

05/18/2023

At the 2023 Great Debates and Updates Conference in Chicago, Illinois, Patrick Forde, MD, makes the case for chemotherapy plus immuno-oncology as the best treatment for patients with lung cancer who have a PD-L1 expression of ≥50%.

At the 2023 Great Debates and...

05/18/2023

Oncology

Vinai Gondi, MD, Northwestern Medicine West Region, Warrensville, IL

Videos

Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer

05/18/2023

Vinai Gondi, MD, explains his position on prophylactic cranial irradiation for patients with small-cell lung cancer, a controversy he addressed in a debate session at the Great Debates and Updates in Lung Cancer conference in Chicago,...

Vinai Gondi, MD, explains his...

05/18/2023

Oncology

Heather Wakelee, MD, Stanford University, Palo Alto, California

Videos

Frontline Treatment Options for Patients With EGFR-Mutated NSCLC

05/18/2023

Heather Wakelee, MD, discusses first-line treatment options for patients with EGFR-mutant non-small cell lung cancer.

Heather Wakelee, MD, discusses...

05/18/2023

Oncology

Recent News

News

Tumor Mutational Status May Predict Recurrence, Survival Patterns for Patients With Early-Stage Non-Small Cell Lung Cancer

11/18/2024

Stephanie Holland ;

According to results from a retrospective analysis, tumor mutational status can potentially predict recurrence and survival patterns for patients with surgically resected, stage I non-small cell lung cancer.

According to results from a...

11/18/2024

Oncology

News

FDA Grants Approval to Revumenib for Patients With R/R Acute Leukemia With KMT2A Translocation

11/17/2024

On November 15, 2024, the FDA approved menin inhibitor revumenib for adult and pediatric patients 1 year and older with relapsed/refractory acute leukemia with KMT2A translocation.

On November 15, 2024, the FDA...

11/17/2024

Oncology

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology